Physician profile
Max L Pavlock
NPI 1891936522
$1,309.85
in general payments reported to CMS, 2019-2025
21 companies · $18.75 in 2025
The $18.75 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2022: $237 · 2023: $328 · 2024: $595 · 2025: $18.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $941.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $941.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $263.13 | 2022-2024 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $176.54 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Davol INC. | $147.09 | 2024 | Arista Ah Flexitip |
| Exact Sciences Corporation | $122.32 | 2023-2024 | Cologuard Collection Kit |
| Amgen INC. | $85.90 | 2019-2023 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.89 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $68.04 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.54 | 2024-2025 | Xifaxan, Trulance |
| Philips North America LLC | $48.87 | 2022-2023 | |
| Glaxosmithkline, LLC. | $40.56 | 2024 | Trelegy Ellipta |
| Lilly USA, LLC | $36.36 | 2022-2024 | Mounjaro, Zepbound |
| Biohaven Pharmaceutical Holding Company LTD. | $32.18 | 2022 | |
| Pfizer INC. | $27.85 | 2022-2023 | |
| Braeburn INC. | $26.41 | 2023-2024 | Brixadi |
| Eisai INC. | $19.95 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $19.20 | 2024 | Glassia |
| Orexo US, INC. | $14.89 | 2023 | Zubsolv |
| Mdd US Operations, LLC | $14.19 | 2019 | |
| Inspire Medical Systems, INC. | $13.60 | 2024 | Inspire |
| Astrazeneca Pharmaceuticals LP | $13.53 | 2024 | Farxiga |
| Merck Sharp & Dohme LLC | $12.81 | 2023 | Belsomra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Max Pavlock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.